NIH Archives
Policy, resources crucial for lung cancer screening: study
Sep. 29, 2022—Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.
Gender differences with bladder pain
Sep. 26, 2022—Gender differences in the pain experiences and treatment needs of people with a urologic pain syndrome could be used to improve interventions, Vanderbilt researchers report.
VUMC to lead AI ethics core for NIH project
Sep. 22, 2022—Vanderbilt researchers will lead and comprise the greater part of an artificial intelligence research ethics core for a National Institutes of Health (NIH) program called Bridge to Artificial Intelligence, or Bridge2AI.
Multisite project seeks to use patients’ voices to help diagnose disease
Sep. 22, 2022—Vanderbilt University Medical Center is partnering with 11 institutions on a $14 million NIH-funded project that aims to establish voice as a biomarker used in clinical care.
Reduced exercise capacity in ICU survivors
Sep. 22, 2022—ICU survivors who have impaired exercise capacity months after discharge may have damaged muscle mitochondria — the energy powerhouses of the cell, Vanderbilt researchers propose.
Nerve cells and cancer progression
Sep. 22, 2022—Immature nerves and neural precursor cells increase in density as a type of premalignant tumor in the pancreas progresses to invasive disease, suggesting that blocking these cells may arrest malignant progression.
Study suggests new mechanism for lipid transporter
Sep. 15, 2022—A new model suggests that a protein involved in the generation of high-density lipoprotein (HDL) works differently than previously thought.
VUMC leads effort to map heart disease-causing genetic variations
Sep. 13, 2022—Researchers from Vanderbilt University Medical Center, Stanford Medicine, the University of Toronto and Brigham and Women’s Hospital in Boston have joined forces to “map” the specific variations in more than 25 key cardiac disease genes that negatively affect heart function.
Enhancing innate immunity in the lung
Sep. 12, 2022—Vanderbilt researchers show that a TLR4 agonist improves lung immune response and survival in a mouse model of bacterial pneumonia, supporting the development of this drug to protect against pneumonia in hospitalized patients.
PheWAS reveals post-COVID-19 diagnoses
Sep. 8, 2022—Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.
Immune cells drive beta cell loss in Type 2 diabetes
Sep. 8, 2022—Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.
Study identifies key player in T cell “education”
Sep. 1, 2022—New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.
